Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming het aandeel van 2017

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,832   -0,033   (-3,82%) Dagrange 0,820 - 0,905 10.889.407   Gem. (3M) 5,9M

Pharming het aandeel van 2017

Volgen
50.750 Posts
Pagina: «« 1 ... 2088 2089 2090 2091 2092 ... 2538 »» | Laatste | Omlaag ↓
  1. Denarius_MCMLXXXVII 18 oktober 2017 00:47
    quote:

    Zinho schreef op 17 oktober 2017 21:54:

    [...]

    eens, de daling was scherp. Ik had de stijging ook minder verwacht dan tot boven de 0,81. Als ik naar mijn grafiekje kijk denk ik ,ja had net als lucasD kunnen verkopen en nu weer terugkopen, of nog een weektje wachten.

    Maar dat is naar mijn mening de lichte paniek zelfs nog zwaar overdreven. Veel wachten op een goed instap moment. Naar mijn idee is dat nu, op 0,75-0,76. Dat is nog altijd 15 tot 16 cent hoger dan de analisten de korte termijn steun op vaststellen.
    Naast de middeling, houd ik per aankooptransactie mijn koopprijs bij, dit geeft een ander plaatje als verkopen tegen je gemiddelde inkoopprijs. Ik verkoop en koop mijn pakket in delen. Die middeling zegt meer iets over je ongerealiseerde winst in totaal. Niets over je verkoop minus werkelijke aanschafwaarde en kosten per aandeel. winst zet ik weer om in meer stukjes. Kijken wie er morgen weer gaan terugkopen of dat de koers wat verder zakt. Ik kijk meer naar first in first out. Maar ja dat kan een beetje een fiscale tik zijn .

    Zijn denk ik ook nog genoeg mensen met een stop/loss op 0,75. we gaan het mee maken.
    Hallo Zinho,

    Misschien dat ik het niet goed begrijp, maar de mensen die vandaag een stoploss hadden op 0,75 hebben deze dan toch al geraakt vandaag?

    Geen aanval maar even een (noob) vraag :)

  2. forum rang 5 antop 18 oktober 2017 03:49
    Wat waren de populairste fondsen in het 3e kwartaal van 2017? We hebben de top 5 voor elke beleggingscategorie voor u op een rij gezet.

    NEDERLAND - AANDELEN
    ArcelorMittal

    Pharming Group

    Ahold Delhaize

    AEGOn
    Galapos

    Tweede plaats voor Pharming dat gaat de eerste plaats worden Q4 en beste van 2017!
    Let maar UP prima instap moment!! Fijne groene dag
  3. jandekkers 18 oktober 2017 04:24
    Dr C:
    Greetings,
    Today I thought that it would be something of interest to discuss the following question passed on by Tony Castaldo, President of the HAEA:
    “My doctor wants me to go on the Ruconest which is a recombinant C1 inhibitor. I recently read a social media post where someone stated that Ruconest caused blood clots. I did see, however, that this person used a port to take her medicine. Another patient posted that Ruconest causes allergic reactions because the C1 inhibitor medicine is derived from the milk of rabbits. Can you provide some expert advice?”
    This is a very timely question for multiple reasons. As many of you are aware there have been recent manufacturing problems at Shire with Cinryze and resulting shortages. CSL has also announced that they will not be able to meet the demand for plasma derived C1 inhibitor (pdC1INH), with their available stocks. Patients are rightfully anxious about running out of medication. Recombinant C1 inhibitor (rC1INH) is identical to the plasma derived C1 inhibitor protein. It is expressed and purified from the milk of transgenic rabbits. Intravenous rC1INH, has been shown to be safe and effective for the treatment of acute attacks of angioedema in a pivotal phase III study. A Phase II study led by Marc Riedl demonstrating efficacy for prophylaxis of attacks has also been published this last year. Fortunately for patients there is no shortage of supply of rC1INH and the manufacturer, Pharming, is dedicated to facilitating availability to patients. As is the case for pdC1INH there have been no significant safety concerns. The questioner raises the issue of rabbit allergy. A warning about rabbit allergy is included in the package insert in the US, which stems from a single case of anaphylaxis during the trials in an individual with rabbit allergy -which had not been disclosed to the investigators. With the manufacturing process there are very low levels of host related impurities (HRIs) in the final product and such that the risk is very low of a reaction even in rabbit allergic patients. A large study in a rabbit allergic cohort has not been done however. In the event that rC1INH is the best option for a patient with a history of rabbit allergy everything has a risk benefit ratio. I would consider skin testing with rabbit and the rC1INH to check prior to use. If the testing for rC1INH is negative and the rabbit positive to err on the side of caution I would then give a test dose of rC1INH under observation in the office to see if it is safe to use. Marc, you have had a lot of experience with rC1INH, could you elaborate further on the rabbit issue?
    Dr R: In order to address the question about allergic reactions to the recombinant human C1INH (rhC1INH/Ruconest), let’s quickly review the process by which it’s manufactured. rhC1INH is produced in rabbits that have been designed to generate the human C1INH protein in their milk. The rabbit milk goes through extensive complex processing to purify the human C1INH protein and remove all other materials. At the end of the process, the medication contains less than 0.002% rabbit-related proteins. So it is an incredibly pure human C1INH medication. To my knowledge, there has been only one confirmed case of an allergic reaction to rhC1INH due to rabbit allergy. This occurred during the early clinical studies with the drug when a young woman treated in the study did not mention to study physicians that she had previously had allergic reactions to rabbits. On receiving the medication, she developed symptoms of a serious allergic reaction, but was treated and recovered without complication. Since that time additional studies have carefully monitored for this potential allergy issue, but no additional allergic reactions related to rabbit allergy have been observed. For a while, the European regulatory agency required that all patients have rabbit allergy testing performed prior to using rhC1INH, but this requirement was removed in early 2016 due to the fact no additional issues with such allergic reactions had been seen. The FDA has never required such testing though of course warns of the possible risk in the medication label. Since FDA-approval, an additional study investigating this issue showed that 4 of 5 individuals with positive allergy tests to rabbit in fact tolerated rhC1INH treatment without any allergy issues. (The fifth individual was the aforementioned woman who had an allergic reaction in the study; she also had the strongest rabbit allergy test of the group.) All told, it appears that rabbit allergy issues related to rhC1INH are exceedingly rare. If someone has a history of allergic reactions to rabbit exposure, then it would be important for them to speak with their physician about rabbit allergy test (blood or skin test) prior to using rhC1INH. But for the vast majority of people, this is not going to be a significant risk or concern, since rabbit allergy is quite uncommon.
  4. jandekkers 18 oktober 2017 04:47
    Repost

    Sustained sales momentum... Since reacquiring US rights to Ruconest in December
    2016, Pharming’s modestly larger but significantly ‘smarter’ sales force (in terms of patient outreach and engagement) has had a dramatic impact on sales of Ruconest, used to treat acute attacks in patients with hereditary angioedema (HAE). According to IMS sales data, average monthly Ruconest revenues in 1H17 were $5m vs just $2.2m in 1H16. Similarly, 2Q17 sales at $16.8m were +25% higher than $13.4m in 1Q17. Sales in July and August have maintained recent momentum, averaging $5.3m (see overleaf).

    ...with potential further benefit from competitor issues... In mid-September, Shire announced yet another supply issue for prophylaxis treatment Cinryze. Recall production at Sanquin’s facility was suspended in 2016 following an FDA warning letter, which has since been resolved, but had an impact on product availability during 2H16. The current supply issue was confirmed by Shire at the recent HAEA National Patient Summit (15-17 September). While the extent and duration of the shortage is unknown, we would logically expect Ruconest, unencumbered so far by supply constraints, to be a beneficiary. Similarly, we also understand that CSL’s recently launched SC prophylaxis product Haegarda is experiencing manufacturing up-scaling issues (also discussed at the HAEA conference). With the potential upside from these issues likely to impact 4Q,
    we have slightly increased our 3Q17 sales estimate to $16.8m (vs $16.1m) but boosted our 4Q17 forecast to $18.5m (vs $17.3m). The pull-through effect of this is an increase to FY17 Ruconest US sales to $66m (vs $64m) and FY18 sales to $93m (vs $80m). Longer term, our peak sales estimate for 2022, for combined sales of Ruconest in both acute and prophylaxis settings, has also increased, c.10% to $313m vs $280m previously.

    ...as pipeline makes good progress. Pharming recently announced it was invited by the FDA to file for accelerated FDA approval (expected in 4Q17) for Ruconest in the prophylaxis setting. This follows compelling Phase II data with twice-weekly Ruconest which compares more than favourably to current standard Cinryze. While we expect current growth in the acute setting (using the existing label) to continue with greater awareness, acceptance and demand from patients/physicians/payers for an ‘on demand’ product like Ruconest, there will clearly be additional use in the prophylaxis setting.

    Ruconest could become the only product available for both uses, with a compelling efficacy, safety and economic profile compared to competitors in the HAE field. Stars are rapidly aligning; increase TP to €1.05; Reiterate Buy. We raise our rNPVbased TP to €1.05 on the back of increased Ruconest forecasts, and greater operational leverage from additional sales in prophylaxis use, having already made the step-up in required investment into the US commercial infrastructure in 1H17. We would also note that fresh pipeline opportunities in Fabry and Pompe diseases are not specifically included in our model, offering further potential upside. The shifting dynamics in the HAE market increasingly appear to favour a recombinant, ‘on demand’ product like Ruconest, over expensive, blood-based products (with continual manufacturing constraints) with
    questionable suitability for prophylaxis use.
  5. jandekkers 18 oktober 2017 05:05
    Hereditary Angioedema Market to be Worth US$3.81 Billion by 2025: Initiatives to Generate Awareness by Physicians and Patient Bodies Drive Growth

    SOURCE Transparency Market Research

    ALBANY, New York, August 23, 2017 /PRNewswire/ --

    Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016.

    Depending upon the class of drugs, the global hereditary angioedema market can be segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor, among others including conventional and pipeline. The C1 esterase inhibitor can be further divided into drugs such as Cinryze, Berinert, and Ruconest. Among them, C1 esterase inhibitor, accounted for more than half the share in the market in 2016 and going forward too, the segment is slated to dominate the market on account of its use in treatment of prophylactic and severe HAE attack. The emergence of novel products will aid the segment to hold on to its leading share in the future.

    Geography-wise, North America, Europe, and Rest of the World are the key regions in the global hereditary angioedema market. At present, North America accounts for a leading position and in the upcoming years too is expected to retain its dominant share by rising at a healthy 8.3% CAGR between 2017 and 2025. This is because of the superior healthcare infrastructure and strong support from public and private sector in terms of reimbursements. Increasing knowledge about HAE among patients has resulted better methods of diagnosis of HAE and adoption of specialty drugs for treatment of HAE - this is also expected to catalyze growth in the market.

    Hereditary angioedema is a rare disease that is estimated to affect 1 in 30,000 to 1 in 50,000 people worldwide. Hereditary angioedema is often mistaken for common allergic reactions and abdominal pain due to lack of awareness both among physicians and patients. It is estimated that around 40% of the affected patient are diagnosed correctly for HAE in the U.S. and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.

    "Specialty hereditary angioedema drugs are offered orphan drug designation across the markets which offers them market exclusivity and several incentives in the regional markets. The frequency and severity of HAE attacks is found to be increased with triggers such as stress, anxiety, minor surgeries, hormone replacement therapies and ACE inhibitors used for treatment of hypertension. According to World Allergy Organization, an estimated 40 million people are receiving ACE inhibitor treatment annually. The projected rise in incidences of HAE attacks is estimated to drive growth for global hereditary angioedema market during the forecast period from 2017 to 2025," explains the lead analyst of the TMR report.

    Acting as a hindrance to the market, on the other hand, is a few approved specialty hereditary angioedema drugs which makes them highly expensive.

    This review is based on the findings of a TMR report, titled, "Hereditary Angioedema Market (Drug Class - C1 Esterase Inhibitor (Cinryze, Berinert, and Ruconest), Selective Bradykinin B2 Receptor Antagonist (Firazyr), and Kallikrein Inhibitor (Kalbitor); Route of Administration - Intravenous, Subcutaneous Injection, and Oral; Distribution Channel - Hospital Pharmacies and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025."

    C1 Esterase Inhibitor
    Cinryze
    Berinert
    Ruconest
    Selective Bradykinin B2 Receptor Antagonist
    Firazyr
    Kallikrein Inhibitor
    Kalbitor
    Others
    Conventional Drugs (attenuated androgens, antifibrinolytic agents
    Pipeline Products (DX-2930, BCX-7353)
    Global Hereditary Angioedema Market, by Route of Administration

    Intravenous
    Subcutaneous Injection
    Oral
    Global Hereditary angioedema Market, by Distribution Channel

    Hospital Pharmacies
    Retail Pharmacies
    Others
    Global Hereditary Angioedema Market, by Geography

    North America
    Europe
    Rest of the World
  12. [verwijderd] 18 oktober 2017 07:40
    quote:

    thx schreef op 18 oktober 2017 00:27:

    Misschien oorzaak daling sinds gisteren? Uitoefening warrants?

    AMS_20171016_05775_EUR
    Issued-16 Oct 2017
    Effective-17 Oct 2017
    expand CE - Shares - Capital increase expand PHARMING GROUP

    Inderdaad uitbreiding geplaatst aantal aandelen, nu de details nog.

    www.aex.nl/listview/notice/NL00103910...

    Past wel zo'n beetje in het rijtje:
    1Q/ 2017 resultaten op 17 mei. Op 15 mei meldingen Empery en S. Gerber (vermindering belang)
    1H/ 2017 resultaten op 27 juli. Op 19 juli melding S. Gerber afbouw tot 4,99%. Op 28 juli melding G-J.Hageman nieuw met Certificaten gewoon aandeel A (3,29%), op 31 juli melding S. Gerber vermindering belang < 3% (2,26%).

    Q3/2017 resultaten op 26 oktober. Op 16 oktober uitbreiding geplaatst aantal aandelen doorgeven aan Euronext, op de markt op 17 oktober. Wie, wat, hoeveel nog onbekend.

  16. [verwijderd] 18 oktober 2017 08:05
    quote:

    thx schreef op 18 oktober 2017 00:27:

    Misschien oorzaak daling sinds gisteren? Uitoefening warrants?

    AMS_20171016_05775_EUR
    Issued-16 Oct 2017
    Effective-17 Oct 2017
    expand CE - Shares - Capital increase expand PHARMING GROUP

    --------------

    Wat fijn dat je dit zag staan, kunnen we nu weer rustig aan de koffie ;-)
  20. [verwijderd] 18 oktober 2017 08:17
    quote:

    geraldw schreef op 18 oktober 2017 08:14:

    Gister warranta of geen warrants,we gaan vandaag weer HURRY UP zal wel niet hard gaan maar we gaan weer groen zien vandaag,Allemaal groetjes uit twente tubbergen (maby evve 5 minuutjes rood van paar dooie konijntjes maar dan het groen weer in)
    Gaan nog wel eerst een paar centjes af hoor.
50.750 Posts
Pagina: «« 1 ... 2088 2089 2090 2091 2092 ... 2538 »» | Laatste |Omhoog ↑

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  2. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster
  3. Pharming brengt bod op Abliva AB uit
  4. Moeizame week voor financials
  5. Weekoverzicht: vastgoed uit de gratie, winst voor automotive en chipaandelen
  6. Fundlogic verkleint belang in Pharming
  7. Fundlogic meldt belang in Pharming
  8. Jefferies: positieve studiedata Pharming vergroten doelgroep Joenja
  9. AEX gaat vlakke opening tegemoet, Pharming en quantumchip Alphabet stelen de show
  10. Pharming meldt positieve studieresultaten met leniolisib